Physician profile
Jonathan Fox
NPI 1417913187
$1,755.83
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.28 · 2020: $76.81 · 2021: $481 · 2022: $423 · 2023: $367 · 2024: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.37 | 2021-2024 | |
| Lilly USA, LLC | $187.35 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Antares Pharma, INC. | $178.35 | 2021 | |
| Abbott Laboratories | $172.02 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $163.23 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $101.21 | 2024 | Synchromedii, Intellis Adaptivestim |
| Pfizer INC. | $85.94 | 2023-2024 | |
| Amgen INC. | $66.02 | 2022-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $64.30 | 2022-2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $63.67 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $56.39 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.41 | 2022 | |
| Phadia US INC. | $41.75 | 2020-2022 | |
| Shield Therapeutics INC | $23.03 | 2022 | |
| Glaxosmithkline, LLC. | $22.45 | 2023 | Shingrix, Arexvy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.27 | 2023 | Veozah |
| Hologic Sales and Service, LLC | $17.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.53 | 2021 | |
| Alvogen INC | $16.76 | 2023 | Teriparatide |
| Neurelis, INC. | $16.45 | 2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.02 | 2021 | |
| Allergan, INC. | $14.96 | 2020 | |
| Novo Nordisk INC | $13.37 | 2021 | |
| Cranial Technologies, INC | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.